Endo International Plc
(NASDAQ : ENDP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOMedicines Company
-1.89%46.7920.3%$139.98m
VRXValeant Pharmaceuticals International, Inc.
-0.95%22.8614.1%$134.51m
AMRNAmarin Corporation Plc Sponsored ADR
-0.70%17.051.8%$104.05m
JAZZJazz Pharmaceuticals Plc
-0.93%130.542.3%$62.01m
PRGOPerrigo Co. Plc
-0.99%55.176.8%$61.49m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.05%137.576.2%$59.04m
SAGESAGE Therapeutics, Inc.
-0.77%163.088.6%$59.03m
CTLTCatalent Inc
0.00%50.842.4%$42.62m
ENDPEndo International Plc
-5.73%3.878.8%$40.47m
MNKMallinckrodt Plc
-7.01%2.5220.9%$34.53m
UTHRUnited Therapeutics Corporation
-1.20%84.8414.3%$34.26m
ICPTIntercept Pharmaceuticals, Inc.
-1.20%69.1116.9%$31.25m
ICLRICON Plc
0.48%151.384.1%$27.89m
PTLAPortola Pharmaceuticals, Inc.
-0.88%30.506.7%$27.38m
AERIAerie Pharmaceuticals, Inc.
-3.07%22.096.8%$26.67m

Company Profile

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.